PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review

被引：48
|
作者：
Handelsman, Yehuda [1 ]
Lepor, Norman E. [2 ]
机构：
[1] Metab Inst Amer, 18372 Clark St 212, Tarzana, CA 91356 USA
[2] Cedars Sinai Heart Inst, Beverly Hills, CA USA
来源：
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2018年 / 7卷 / 13期
关键词：
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; EVOLOCUMAB AMG 145; STATIN-INTOLERANT PATIENTS; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; LOWERING EFFICACY; LDL-CHOLESTEROL; POOLED ANALYSIS; ADD-ON; CLINICAL ENDOCRINOLOGISTS;
D O I：
10.1161/JAHA.118.008953
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：36
相关论文
共 50 条
  • [1] Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
    Ballve Behr, Paulo Eduardo
    Moriguchi, Emilio Hideyuki
    Castro, Iran
    Bodanese, Luiz Carlos
    Dutra, Oscar Pereira
    Leaes, Paulo Ernesto
    Pimentel Filho, Pedro
    [J]. ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2018, 111 (01) : 104 - 107
  • [2] PCSK9 inhibitors and diabetes risk
    Krome, Susanne
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2018, 13 (02) : 140 - 141
  • [3] PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
    Jia, Xiaoming
    Al Rifai, Mahmoud
    Saeed, Anum
    Ballantyne, Christie M.
    Virani, Salim S.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2022, 18 : 555 - 566
  • [4] Lipid control in patients at high cardiovascular risk: focus on PCSK9 inhibition
    Filardi, Pasquale Perrone
    Paolillo, Stefania
    Trimarco, Bruno
    [J]. GIORNALE ITALIANO DI CARDIOLOGIA, 2015, 16 (01) : 44 - 51
  • [5] Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk
    Cesaro, Arturo
    Gragnano, Felice
    Fimiani, Fabio
    Moscarella, Elisabetta
    Diana, Vincenzo
    Pariggiano, Ivana
    Concilio, Claudia
    Natale, Francesco
    Limongelli, Giuseppe
    Bossone, Eduardo
    Calabro, Paolo
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (05) : 556 - 558
  • [6] MANAGEMENT OF HYPERCOLESTEROLEMIC SUBJECTS AT HIGH CARDIOVASCULAR RISK WITH PCSK9 INHIBITORS: A "REAL LIFE" EXPERIENCE IN A LIPID CLINIC IN SICILY
    Giammanco, Antonina
    Noto, D.
    Gagliardo, Carola Maria
    Polizzi, Francesco
    Furnari, Maria Laura
    Fasciana, Teresa Maria Grazia
    Ganci, Antonina
    Barbagallo, C. M.
    Averna, M. R.
    Cefalu, A. B.
    [J]. ATHEROSCLEROSIS, 2024, 395
  • [7] PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?
    Parhofer, K. G.
    [J]. HERZ, 2016, 41 (03) : 217 - 223
  • [8] A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
    Chen, Bo
    Shi, Xin
    Cui, Yanping
    Hou, Aiping
    Zhao, Pengjun
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (20) : 1790 - 1817
  • [9] QUALITY OF LIFE IMPROVEMENT IN HIGH AND VERY HIGH CARDIOVASCULAR RISK PATIENTS TREATED WITH PCSK9 INHIBITORS
    Cesaro, A.
    Gragnano, F.
    Fimiani, F.
    Moscarella, E.
    Pariggiano, I.
    Diana, V.
    Carfora, V.
    Conte, M.
    Falato, S.
    Cesarano, M.
    Di Maio, D.
    Calabro, P.
    [J]. ATHEROSCLEROSIS, 2019, 287 : E199 - E199
  • [10] TREATMENT WITH PCSK9 INHIBITORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT VERY HIGH CARDIOVASCULAR RISK
    Amaro, Jose Manuel
    Fernandez, Florentino Villanego
    Munoz, Javier Naranjo
    Orellana, Cristhian
    Vigara Sanchez, Luis Alberto
    Cazorla Lopez, Juan Manuel
    Mejia, Carlos Narvaez
    Alonso, Marta
    Aguilera, Aurora
    Mazuecos Blanca, Andmaria Auxiliadora
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I613 - I615
12345